Anemia

The approval of Ayrmid’s omidubicel-onlv makes it the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia.

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

If approved, the investigative therapy could provide a frontline treatment for patients with SAA who do not have matched sibling donors for cell transplantation.

The FDA approved generic versions of Venofer (iron sucrose) injection from Viatris Inc and Amphastar Pharmaceuticals.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in hematology.

A relatively quiet quarter for hematology, punctuated by both successes and failures in clinical trials and a handful of Orphan Drug and Fast Track designations.

The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.

Hereditary hemorrhagic telangiectasia has no approved treatments; this designation, in addition to the European Medicines Agency granting a positive opinion, positions DIAG723 to be the first.

Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.

Investigators compared the medications across various patient cohorts with different causes of anemia, finding evidence almost uniformly in favor of FCM.

A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

A recent study has indicated that FCH results in better tolerability and medication compliance due to lowered risk of adverse gastrointestinal effects.

Iron deficient diets can lead to anemia and various other health complications in adulthood.

Iron deficiency affects millions globally, especially women, yet remains underdiagnosed. Regular screening can prevent severe health issues and improve lives.

Interim results from the ongoing trial indicated achievement of all efficacy endpoints, with no safety concerns reported.

A study reveals a significant link between iron deficiency anemia and increased ischemic stroke risk in young adults, highlighting urgent screening needs.

A mixture of thalidomide and hydroxyurea outperformed hydroxyurea alone in all primary outcomes.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Investigators believe the connection may account for a substantial number of anemia cases in children.

Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.

Despite no direct correlation being identified, this research highlights a potential association between the two conditions.

Investigators examined the safety of the recalled sickle cell disease medication through retrospective analysis of an FDA database.

Investigators encourage further study of treatment and therapy methods for childhood IBD.

Patient-reported outcome measures display positive trends after hematopoietic stem cell transplantation for patients with sickle cell disease.